Physicians and gastroenterologists, nurse practitioners, and physician assistants
Inflammatory bowel diseases; Crohn's disease; Ulcerative colitis
Miguel Regueiro, MD
Miguel Regueiro, MD
Chair, Department of Gastroenterology and Hepatology
Professor, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH
Hans Herfarth, MD, PhD
Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC
1. | Decide which medical treatment to use in acute IBD flares and for long-term disease management | 2. | Identify IBD characteristics for which surgery is indicated |
1. | Decide which medical treatment to use in acute IBD flares and for long-term disease management |
2. | Identify IBD characteristics for which surgery is indicated |
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Hans Herfarth, MD, PhD, has affiliations with Alivio, Allergan, AMAG, Boehringer-Ingelheim, Celtrion, Finch, Lycera, Merck, Pfizer, PureTech, Seres (Consultant); Artizan, Pfizer (Research).
Miguel Reguerio, MD, has affiliations with AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Miraca Labs, Pfizer, Salix, Seres, Takeda, UCB (Advisory Board, Consultant); AbbVie, Janssen, Takeda (Research); AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB (Unrestricted Educational Grants).
Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose. The Crohn’s & Colitis Foundation planners and managers have nothing to disclose.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period May 2, 2019 through May 1, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.
Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |